Labcorp and PathAI Join Forces to Revolutionize Digital Pathology Nationwide

Labcorp and PathAI Partnership: A New Era for Digital Pathology

In a groundbreaking move, Labcorp, a prominent global player in comprehensive laboratory services, has expanded its partnership with PathAI. This collaboration focuses on deploying the FDA-cleared digital pathology platform, AISight® Dx, across Labcorp's vast network of anatomic pathology labs and hospital collaborations nationwide. This initiative marks a significant advancement in the integration of artificial intelligence within the realm of diagnostics.

The AISight® Dx technology is designed to revolutionize how pathology is conducted by transitioning from traditional methods to fully digital workflows. Pathologists will now be able to manage and review slides digitally, using AI-driven techniques to enhance the diagnostic process. The platform's cloud-based capabilities ensure that pathologists can access and collaborate on cases more efficiently, which is expected to positively impact both turnaround times and patient care.

Dr. Marcia Eisenberg, Labcorp's chief scientific officer, emphasized the company's commitment to modernizing pathology with advanced technology. She stated, "Labcorp is committed to building a modern, AI-powered infrastructure that sets a new standard for efficiency, collaboration and innovation in pathology." The integration of PathAI’s technology is a pivotal step in this journey, providing clinicians with tools that deliver consistent and faster results for patients, ensuring they receive the necessary care without delay.

The AISight Dx platform enables several critical features, including fully digital workflow management for case handling, slide reviews, collaborative efforts among pathologists, and annotation processes. It further incorporates AI-powered image analysis and secure storage, significantly enhancing overall operational efficiency. As Labcorp aims to streamline its workflows, the advanced capabilities of AISight Dx stand to improve collaboration within its existing pathology services and contribute towards precision medicine initiatives.

Dr. Andy Beck, CEO and co-founder of PathAI, remarked on the significance of this partnership by stating, "Labcorp's leadership in diagnostics makes them an ideal partner in our mission to modernize pathology through software and AI." The deployment of AISight Dx across Labcorp’s network will ensure that high-quality digital pathology practices become a standard across multiple medical settings, making it easier for healthcare professionals to provide quality care at scale.

This partnership builds upon Labcorp’s previous investment in PathAI back in 2019, which laid the groundwork for further collaboration, including support for clinical trials and validation of novel AI-pathology solutions. This latest venture showcases a continued commitment to advancing medical technologies that ultimately lead to improved outcomes for patients.

For those interested in understanding more about Labcorp's initiatives and capabilities in digital pathology and AI, further information is available at Labcorp's official website.

Labcorp, a leader in the laboratory services industry, employs nearly 71,000 people and operates in around 100 countries. The company has supported the approval of over 85% of new drugs and therapeutic products by the FDA in 2025 while conducting more than 750 million tests globally. Through its comprehensive laboratory capabilities, Labcorp is poised to transform the future of diagnostics through innovation and technology.

As this partnership evolves, it is essential to monitor how the integration of AI in pathology will continue to shape healthcare practices and patient care standards. The commitment to advancing diagnostic services is sure to set a precedent for future collaborations within the medical landscape.